Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	Hepatology 2012 (546 pages, free PDF) Hepatitis C 2012 (150 pages, free PDF)	Free Medical Books

Prostate Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 76 articles: HTML format Text format

Single Articles

April 2012
1. FISCH MJ , Lee JW, Weiss M, Wagner LI, et al
   Prospective, Observational Study of Pain and Analgesic Prescribing in Medical Oncology Outpatients With Breast, Colorectal, Lung, or Prostate Cancer.
   J Clin Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. BUYYOUNOUSKI MK , Pickles T, Kestin LL, Allison R, et al
   Validating the Interval to Biochemical Failure for the Identification of Potentially Lethal Prostate Cancer.
   J Clin Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. YU EY , Kuo KF, Gulati R, Chen S, et al
   Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer.
   J Clin Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   March 2012
4. KELLY WK , Halabi S, Carducci M, George D, et al
   Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401.
   J Clin Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. TODD M , Meyers ML, Charnas R, Acharya M, et al
   Fast and flawed or scientifically sound: the argument for administering oral oncology drugs during fasting.
   J Clin Oncol. 2012;30:888-9.
   PubMed     Text format     Related articles   
   
   
   
   
6. NEEDLE MN
   The virtue of low-flow toilets.
   J Clin Oncol. 2012;30:890.
   PubMed     Text format     Related articles   
   
   
   
   February 2012
7. BARRY MJ , Gallagher PM, Skinner JS, Fowler FJ Jr, et al
   Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men.
   J Clin Oncol. 2012;30:513-8.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. COOPERBERG MR , Odisho AY, Carroll PR
   Outcomes for radical prostatectomy: is it the singer, the song, or both?
   J Clin Oncol. 2012;30:476-8.
   PubMed     Text format     Related articles   
   
   
   
   
9. POYET C , Hof D, Sulser T, Muntener M, et al
   Artificial prostate-specific antigen persistence after radical prostatectomy.
   J Clin Oncol. 2012;30:e62-3.
   PubMed     Text format     Related articles   
   
   
   
   
10. LAGRO J , Studenski SA, Olde Rikkert MG
    Predicting chemotherapy toxicity in older adults and the importance of geriatric assessment.
    J Clin Oncol. 2012;30:560.
    PubMed     Text format     Related articles   
    
    
    
    January 2012
11. DENNIS ER , Jia X, Mezheritskiy IS, Stephenson RD, et al
    Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate Cancer.
    J Clin Oncol. 2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2011
12. KATZ A
    "Doc, please don't tell my wife...".
    J Clin Oncol. 2011;29:4839-40.
    PubMed     Text format     Related articles   
    
    
    
    
13. EFSTATHIOU E , Titus M, Tsavachidou D, Tzelepi V, et al
    Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. NELSON PS
    Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
15. HINNEN KA , Schaapveld M, van Vulpen M, Battermann JJ, et al
    Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.
    J Clin Oncol. 2011;29:4510-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2011
16. FINK M
    Febrile neutropenia and infection in the ASCENT studies.
    J Clin Oncol. 2011;29:4337.
    PubMed     Text format     Related articles   
    
    
    
    October 2011
17. D'AMICO AV , Chen MH, Crook J, Armstrong JG, et al
    Duration of Short-Course Androgen Suppression Therapy and the Risk of Death As a Result of Prostate Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. RATAIN MJ
    Flushing oral oncology drugs down the toilet.
    J Clin Oncol. 2011;29:3958-9.
    PubMed     Text format     Related articles   
    
    
    
    
19. CHING CB , Chen L, Fergany A
    Prostatic urethral recurrence of urachal adenocarcinoma.
    J Clin Oncol. 2011;29:e736-8.
    PubMed     Text format     Related articles   
    
    
    
    September 2011
20. RYAN CJ , Tindall DJ
    Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically.
    J Clin Oncol. 2011;29:3651-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. PILI R , Haggman M, Stadler WM, Gingrich JR, et al
    Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. ALIBHAI SM
    Cardiovascular toxicity of androgen deprivation therapy: a new door opens.
    J Clin Oncol. 2011;29:3500-2.
    PubMed     Text format     Related articles   
    
    
    
    
23. PUNNEN S , Cooperberg MR, Sadetsky N, Carroll PR, et al
    Androgen deprivation therapy and cardiovascular risk.
    J Clin Oncol. 2011;29:3510-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
24. SAYLOR PJ , Lee RJ, Smith MR
    Emerging Therapies to Prevent Skeletal Morbidity in Men With Prostate Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. SMALL EJ , de Bono JS
    Prostate Cancer: Evolution or Revolution?
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
26. RUBIN MA , Maher CA, Chinnaiyan AM
    Common Gene Rearrangements in Prostate Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. SCHER HI , Morris MJ, Basch E, Heller G, et al
    End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. PINSKY PF
    Point estimates of number needed to treat/screen are insufficient without characterization of their uncertainty.
    J Clin Oncol. 2011;29:3336.
    PubMed     Text format     Related articles   
    
    
    
    
29. VODOVAR D , Mongardon N, Moachon L, Arnaout M, et al
    Severe docetaxel overdose induced by pharmacokinetic interaction with dronedarone.
    J Clin Oncol. 2011;29:e694-5.
    PubMed     Text format     Related articles   
    
    
    
    
30. SERUGA B , Tannock IF
    Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. CHA E , Fong L
    Immunotherapy for Prostate Cancer: Biology and Therapeutic Approaches.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. COOPERBERG MR , Carroll PR, Klotz L
    Active Surveillance for Prostate Cancer: Progress and Promise.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. VICKERS AJ
    Prediction models: revolutionary in principle, but do they do more good than harm?
    J Clin Oncol. 2011;29:2951-2.
    PubMed     Text format     Related articles   
    
    
    
    June 2011
34. NAM RK , Kattan MW, Chin JL, Trachtenberg J, et al
    Prospective Multi-Institutional Study Evaluating the Performance of Prostate Cancer Risk Calculators.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. FLESHNER NE , Kapusta L, Donnelly B, Tanguay S, et al
    Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium.
    J Clin Oncol. 2011;29:2386-90.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. BALINK H , Hemmelder MH, de Graaf W, Grond J, et al
    Scintigraphic diagnosis of Erdheim-Chester disease.
    J Clin Oncol. 2011;29:e470-2.
    PubMed     Text format     Related articles   
    
    
    
    May 2011
37. PORTEN SP , Whitson JM, Cowan JE, Cooperberg MR, et al
    Changes in Prostate Cancer Grade on Serial Biopsy in Men Undergoing Active Surveillance.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. TZELEPI V , Efstathiou E, Wen S, Troncoso P, et al
    Persistent, Biologically Meaningful Prostate Cancer After 1 Year of Androgen Ablation and Docetaxel Treatment.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. YANG M , Xie W, Mostaghel E, Nakabayashi M, et al
    SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. VAN DOORMAAL FF , Di Nisio M, Otten HM, Richel DJ, et al
    Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.
    J Clin Oncol. 2011;29:2071-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. GLIGOROV J , Fajac A, Bernaudin JF
    Castration-dependent pharmacokinetics of docetaxel: do sex and/or ABCB1 polymorphism also matter?
    J Clin Oncol. 2011;29:e454-5.
    PubMed     Text format     Related articles   
    
    
    
    
42. PENNEY KL , Sinnott JA, Fall K, Pawitan Y, et al
    mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
43. HENDRICKSON WK , Flavin R, Kasperzyk JL, Fiorentino M, et al
    Vitamin D Receptor Protein Expression in Tumor Tissue and Prostate Cancer Progression.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
44. MARBERGER M , McConnell JD, Fowler I, Andriole GL, et al
    Biopsy misidentification identified by DNA profiling in a large multicenter trial.
    J Clin Oncol. 2011;29:1744-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. DRAZER MW , Huo D, Schonberg MA, Razmaria A, et al
    Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.
    J Clin Oncol. 2011;29:1736-43.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
46. DORFF TB , Flaig TW, Tangen CM, Hussain MH, et al
    Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. SCHER HI , Jia X, Chi K, de Wit R, et al
    Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. BOIKE TP , Lotan Y, Cho LC, Brindle J, et al
    Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. TOSOIAN JJ , Trock BJ, Landis P, Feng Z, et al
    Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. D'AMICO AV
    Future of Treatment for Low-Risk Prostate Cancer: For All, for Some, or for None?
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    March 2011
51. BACH PB , Vickers AJ
    Do the Data Support the Comorbidity Hypothesis for the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Results?
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
52. NGUYEN PL , Gu X, Lipsitz SR, Choueiri TK, et al
    Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. FROEHNER M
    Prostate Cancer-Specific Survival in Elderly Patients.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    February 2011
54. ALBERTSEN PC , Moore DF, Shih W, Lin Y, et al
    Impact of Comorbidity on Survival Among Men With Localized Prostate Cancer.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. HENRY DH , Costa L, Goldwasser F, Hirsh V, et al
    Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. LOEB S , Vonesh EF, Metter EJ, Carter HB, et al
    What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?
    J Clin Oncol. 2011;29:464-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
57. CROOK JM , Gomez-Iturriaga A, Wallace K, Ma C, et al
    Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial.
    J Clin Oncol. 2011;29:362-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
58. KENFIELD SA , Stampfer MJ, Giovannucci E, Chan JM, et al
    Physical Activity and Survival After Prostate Cancer Diagnosis in the Health Professionals Follow-Up Study.
    J Clin Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
59. CARROLL PR , Whitson JM, Cooperberg MR
    Serum Prostate-Specific Antigen for the Early Detection of Prostate Cancer: Always, Never, or Only Sometimes?
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
60. BECHIS SK , Carroll PR, Cooperberg MR
    Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
61. COOPERBERG MR , Cowan JE, Hilton JF, Reese AC, et al
    Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
62. ALIBHAI SM , Breunis H, Timilshina N, Johnston C, et al
    Impact of Androgen Deprivation Therapy on Physical Function and Quality of Life in Men With Non-Metastatic Prostate Cancer.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. ALIBHAI SM , Breunis H, Timilshina N, Marzouk S, et al
    Impact of Androgen-Deprivation Therapy on Cognitive Function in Men With Nonmetastatic Prostate Cancer.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
64. CRAWFORD ED , Grubb R 3rd, Black A, Andriole GL Jr, et al
    Comorbidity and Mortality Results From a Randomized Prostate Cancer Screening Trial.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
65. NGUYEN V , Gurney H, van der Poorten D
    Paraneoplastic Hepatic Dysfunction in Metastatic Prostate Cancer: The Role of Cytokine Dysregulation.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
66. ATTARD G , Reid AH, de Bono JS
    Abiraterone acetate is well tolerated without concomitant use of corticosteroids.
    J Clin Oncol. 2010;28:e560-1.
    PubMed     Text format     Related articles   
    
    
    
    
67. PARDO Y , Guedea F, Aguilo F, Fernandez P, et al
    Quality-of-Life Impact of Primary Treatments for Localized Prostate Cancer in Patients Without Hormonal Treatment.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. SANDA MG
    Urinary Obstructive Problems Exposed But Hormonal Health-Related Quality-of-Life Concerns Eschewed in Prostate Cancer Quality-of-Life Study.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
69. SINGH PB , Ahmed HU, Emberton M
    Active surveillance: is there a need for better risk stratification at the outset?
    J Clin Oncol. 2010;28:e513.
    PubMed     Text format     Related articles   
    
    
    
    
70. SANDHU AP
    Pitfalls of retrospective and nonrandomized comparison of treatment modalities.
    J Clin Oncol. 2010;28:e520.
    PubMed     Text format     Related articles   
    
    
    
    September 2010
71. AZOULAY L , Suissa S
    Statins in the Prevention of Prostate Cancer Recurrence: Are Certain Biases Exaggerating the Results?
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
72. DANIELL HW
    Smoking, Obesity, and Statin Therapy in the Prognosis of Prostate Cancer.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
73. FRANKE RM , Carducci MA, Rudek MA, Baker SD, et al
    Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer.
    J Clin Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
74. FOLKERD EJ , Dowsett M
    Influence of sex hormones on cancer progression.
    J Clin Oncol. 2010;28:4038-44.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
75. WEI EK , Wolin KY, Colditz GA
    Time course of risk factors in cancer etiology and progression.
    J Clin Oncol. 2010;28:4052-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
76. ROACH M 3RD , Lawton CA, Chen J
    To treat pelvic nodes or not? Greater testicular scatter does not explain the results of randomized trials.
    J Clin Oncol. 2010;28:e450-2.
    PubMed     Text format     Related articles   
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: